MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
2.430
-0.110
-4.33%
Closed 16:00 04/12 EDT
OPEN
2.540
PREV CLOSE
2.540
HIGH
2.570
LOW
2.410
VOLUME
57.79K
TURNOVER
0
52 WEEK HIGH
4.750
52 WEEK LOW
1.500
MARKET CAP
92.24M
P/E (TTM)
-4.0833
1D
5D
1M
3M
1Y
5Y
Diamedica Therapeutics Updates SEC Filing
TipRanks · 4d ago
Weekly Report: what happened at DMAC last week (0401-0405)?
Weekly Report · 6d ago
Weekly Report: what happened at DMAC last week (0325-0329)?
Weekly Report · 04/01 09:51
Weekly Report: what happened at DMAC last week (0318-0322)?
Weekly Report · 03/25 09:52
DiaMedica Therapeutics files for $100M mixed securities shelf
DiaMedica Therapeutics filed a prospectus related to the offer and sell of $100M mixed securities shelf. This prospectus is not an offer to sell. DiaMedica filed for $100m mixed securities shelf. The company is a biopharmaceutical company.
Seeking Alpha · 03/21 20:55
Diamedica Therapeutics Price Target Cut to $8.00/Share From $11.00 by Craig-Hallum
Dow Jones · 03/21 18:41
Diamedica Therapeutics Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/21 18:41
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Benzinga · 03/21 18:31
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.